Product news

Share this article:
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that the FDA has approved a supplemental New Drug Application for Nexavar (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma, or liver cancer. Nexavar, an oral anticancer drug, is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease.
 
Wyeth, announced that the FDA has approved Protonix (pantoprazole sodium) delayed-release oral suspension, providing adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.
 
AstraZeneca said the FDA has approved once-daily Seroquel XR (quetiapine fumarate) extended-release tablets for maintenance treatment of schizophrenia in adult patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.